INVESTOR NEWS

May 06, 2026

Gentian Diagnostics: First quarter 2026 report

Moss, 6 May 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests,..

May 06, 2026

Gentian Diagnostics ASA terminates NT-proBNP assay development

Moss, 6 May 2026 Following a comprehensive review of performance data and market dynamics, Gentian..

May 06, 2026

Gentian Diagnostics: Ex dividend NOK 0.60 today

Moss, 6 May 2026 The shares in Gentian Diagnostics ASA will be traded ex dividend NOK 0.60 as of today. The..

May 05, 2026

Gentian Diagnostics: Minutes from Annual General Meeting

Moss 5 May, 2026 Gentian Diagnostics ASA has today held its annual general meeting (AGM). All items on the..

Apr 29, 2026

Gentian Diagnostics: Invitation to presentation of first quarter results

Gentian Diagnostics ASA will present its first quarter 2026 results on 6 May 2026 at 09.00 CEST. The..

Apr 20, 2026

Gentian Diagnostics renews long term faecal calprotectin partnership with Bühlmann Laboratories

Moss, 20 April 2026 Gentian Diagnostics, a fast-growing developer and manufacturer of high-quality diagnostic..

Apr 13, 2026

Gentian Diagnostics: Notice of annual general meeting

Gentian Diagnostics ASA’s annual general meeting will be held on Tuesday 5 May 2026 at 11:00 at the company’s..

Apr 10, 2026

Gentian Diagnostics ASA - Registration of share capital increase

Moss, 10 April 2026 Reference is made to Gentian Diagnostics ASA's stock exchange announcement on 12 March..

Mar 20, 2026

Gentian Diagnostics: Annual report 2025

Moss, 20 March 2026 Gentian Diagnostics has today published its annual report for 2025. The annual report and..

Mar 12, 2026

Gentian Diagnostics ASA – Mandatory notification of subscription of shares by primary insiders in Employee Share Purchase Program

Moss, 12 March 2026 Reference is made to Gentian Diagnostics ASA's (the "Company") stock exchange..